IceCure Medical (ICCM) announced it has received a Notice of Allowance for its invention titled “Cryogenic System Connector” from the China National Intellectual Property Administration. The novel cryogenic pump enables IceCure to bring to market a new generation of cryoablation systems with a small footprint for a wide range of clinical applications. It also expands the company’s portfolio of products to include a broader range of thinner cryoprobes and catheters.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical’s Cryoablation Shows Higher Patient Satisfaction in Japan Study
- IceCure Medical Seeks Israeli Approval for Advanced Cryoablation System
- IceCure Medical files for regulatory approval of cryoablation system in Israel
- IceCure Medical Awaits FDA Decision as ProSense® Gains Attention
- Is ICCM a Buy, Before Earnings?